Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)

NCT01012973 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

177

Enrollment

INDUSTRY

Sponsor class

Conditions

Retinal Vein Occlusion

Interventions

BIOLOGICAL: Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)
OTHER: Sham treatment

Sponsor

Bayer

Collaborators

[object Object]